Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ginkgo Bioworks Holdings, Inc.

NYSE: DNA · Life Sciences · 6 alerts · CIK 1830214

Share price
$8.50Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ginkgo Bioworks Holdings, Inc. filings on SEC EDGAR ↗

4:54 PM ET 10-Q
Financial Results

Ginkgo Bioworks Holdings Q3 2026 Results: Net Loss of $41M, Loss Narrows

Ginkgo Bioworks reported a net loss of $170.3 million for the nine months ended September 30, 2026, an improvement from a $232.0 million loss in the prior year period. Total revenue declined significantly to $67.3 million from $106.7 million year-over-year, while the company reduced operating expenses by approximately $87.3 million through restructuring and lower R&D spending.

Key figure
Net loss $41M
4:08 PM ET 8-K
Financial Results

Ginkgo Bioworks Holdings Financial Results

Ginkgo Bioworks reported Q3 2026 revenue of $28 million and a GAAP net loss of $41 million, showing improvement from the prior year's $73 million loss. The company highlighted the sale of its first autonomous lab to Novo and new government contracts with ARPA-H and the NSF as it transitions to a platform focused on Autonomous Labs and Cloud Lab services.

Term
Q3 2026

“Ginkgo now has two core offerings built on one autonomous lab platform. This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF. Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data. With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research.”

Jason Kelly, Co-founder and CEO of Ginkgo Bioworks

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.